Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced
ALK-positive
Alectinib
Atezolizumab
Non–small cell lung cancer
Phase 1b study
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
20
03
2022
revised:
10
06
2022
accepted:
15
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Alectinib is a preferred first-line treatment option for advanced Adults with treatment-naive, stage IIIB/IV, or recurrent In total, 21 patients received more than or equal to 1 dose of alectinib or atezolizumab. As no dose-limiting toxicities were observed in stage 1 (n = 7), the starting dose and schedule were continued into stage 2 (n = 14). Median duration of follow-up was 29 months (range: 1-39). Grade 3 treatment-related adverse events occurred in 57% of the patients, most often rash (19%). No grade 4 or 5 treatment-related adverse events were reported. Confirmed objective response rate was 86% (18 of 21; 95% confidence interval [CI]: 64-97). Median progression-free survival was not estimable (NE) (95% CI: 13 mo-NE), neither was median overall survival (95% CI: 33 mo-NE). The combination of alectinib and atezolizumab is feasible, but increased toxicity was found compared with the individual agents. With small sample sizes and relatively short follow-up, definitive conclusions regarding antitumor activity cannot be made.
Identifiants
pubmed: 35875467
doi: 10.1016/j.jtocrr.2022.100367
pii: S2666-3643(22)00091-1
pmc: PMC9304608
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100367Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022 The Authors.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Thorac Oncol. 2018 May;13(5):682-688
pubmed: 29518553
Target Oncol. 2019 Aug;14(4):417-421
pubmed: 31346927
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Oncologist. 2020 Jul;25(7):562-e1012
pubmed: 32048771
J Clin Oncol. 2021 Mar 20;39(9):1040-1091
pubmed: 33591844
J Thorac Oncol. 2020 Mar;15(3):392-403
pubmed: 31634667